SIM
TPTX

Spark Investment Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Spark Investment Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,500
Closed -$513K – 332
2020
Q1 		$513K Sell
11,500
-12,400
-52% -$659K 0.27% 128
2019
Q4 		$1.49M Buy
+23,900
New +$1.14M 0.17% 172

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Spark Investment Management's TPTX Position: Q2 2020 in Review

Spark Investment Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2020, closing a stake of 11,500 shares — an estimated $513K sold.

Spark Investment Management first reported a position in TPTX in Q4 2019 and held it in 2 quarters. The position peaked at $1.49M in Q4 2019. 158 funds tracked by Wall St. Rank hold TPTX as of Q2 2020.

  • Spark Investment Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Spark Investment Management sold 11,500 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $513K.
  • Spark Investment Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Spark Investment Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.49M in Q4 2019.
  • 158 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.